Clinical trials: Covid-19 Pneumonia
SARS-CoV-2, Influenza A
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag Ultra test in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and LumiraDx SARS-CoV-2 \& Flu A/B…
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, COVID-19
- Trial name
- PURSUE (NCT05728970)
- Testing
- LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
- Where
- 10 sites in United States
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Covid19
Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19
A) Comparing the % of change in each clearances of pro-, and anti-inflammatory mediators (cytokine, chemokines and complement) in the COVID-19 patients treated with CytoSorb as compared to the same patient population who do not…
- Trial name
- NCT04518969
- Testing
- CytoSorb
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- Dr David DE BELS
Covid19
COVID-19 Patients Admitted to the ICU
A retrospective analysis of the adult COVID-19 patients admitted to the ICU. A chart review will be conducted and multiple baseline characteristics, demographics, and treatments given will be recorded.
- Trial name
- NCT04816786
- Testing
- no intervention will be administered, this is a retrospective observational study.
- Where
- Kuwait
- Volunteers
- 100 people
- Sponsor
- Ministry of Health, Kuwait
Sars-CoV2, Critical Illness
COVID-19 and ICU-acquired MDR Bacteria
This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.
- Trial name
- COVID-BMR (NCT04378842)
- Where
- 7 sites in France
- Volunteers
- 368 people
- Sponsor
- University Hospital, Lille
COVID-19, SARS-CoV 2
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest…
- Conditions
- COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease
- Trial name
- AMPoL (NCT04409873)
- Testing
- Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, San Francisco
COVID-19, ARDS, Human
Cardiac Dysfunction in Critically Ill Covid-19 Patients
We conducted an observation sub-study of the prospective randomized controlled trial "High Dose Inhaled Nitric Oxide in Acute Hypoxemic Respiratory Failure", in which we analysed the echocardiographic data collected both at…
- Conditions
- COVID-19, ARDS, Human, Cardiac Failure, Right Ventricular Dysfunction
- Trial name
- NCT06197256
- Where
- Sweden
- Volunteers
- 39 people
- Sponsor
- Region Stockholm
COVID-19 Pneumonia
A New Scoring Model to Diagnose COVID-19 Using Lung Ultrasound in the Emergency Department
Mortality in COVID-19 patients is significantly correlated with age, fever duration, cardiac history, and B-profile and areas of consolidation in LUS.
- Trial name
- LungUltrasound (NCT05077202)
- Testing
- ultra sound
- Where
- Egypt
- Volunteers
- 82 people
- Sponsor
- Zagazig University
Safety, SARS-CoV2 Infection
Efficacy of Ivermectin in COVID-19
The newly emerged corona virus disease 2019 (COVID-19) has spread to all over the world, with recent estimates of more than 236 million cases diagnosed and led to 4.8 million deaths as November 20211 .Therapeutic approaches are…
- Conditions
- Safety, SARS-CoV2 Infection, Ivermectin Poisoning, Effect of Drug
- Trial name
- NCT05076253
- Testing
- Ivermectin
- Where
- Thailand
- Volunteers
- 72 people
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
Transcranial Direct Current Stimulation, Mental Health Issue
Promote Brain Resilience for the Coronavirus (COVID-19) Pandemic
Background: By the end of 2020, the coronavirus disease (COVID-19) pandemic resulted in over 84 million cases and nearly 2 million deaths.
- Conditions
- Transcranial Direct Current Stimulation, Mental Health Issue, Public Health, Resilience, Psychological
- Trial name
- MBNPR (NCT05293431)
- Testing
- Transcranial Alternate Current Stimulation
- Where
- Spain
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Institut Guttmann
Covid19
Retrospective Study of ImmunoFormulation for COVID-19
Multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated or not with IMUNO TF ® and a combination of nutraceuticals and who have tested positive in a COVID-19 diagnostic…
- Trial name
- NCT04666753
- Testing
- ImmunoFormulation
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fagron Iberica S.A.U.
COVID-19
Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population
Background: In the Covid-19 pandemic context, all healthcare teams face clinical, organizational and technical challenges given the contagion, severity and mortality characteristics of the disease.
- Trial name
- NCT04344145
- Where
- 5 sites in Belgium
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Université Libre de Bruxelles
COVID-19, SARS-CoV 2
Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in…
- Trial name
- NCT04365153
- Testing
- Canakinumab Injection 600mg, Canakinumab Injection 300mg
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- The Cleveland Clinic
Secondary Sclerosing Cholangitis, COVID-19
SSC-COVID in Patients After COVID-19
Analysis of occurrence of SSC-COVID in SARS-CoV-2-patients after the first wave of COVID-pandemic
- Trial name
- NCT05233553
- Testing
- control of liver enzymes
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- University Hospital Tuebingen
COVID-19
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
The study is comprised of two parts: safety evaluation part (Phase I/II) and the pivotal study (Phase III) to evaluate the efficacy and safety of the combination of SCTA01 \& SCTA01C compared to placebo in addition to Standard of…
- Trial name
- NCT05156645
- Testing
- SCTA01 and SCTA01C
- Sponsor
- Sinocelltech Ltd.
Covid-19
Rapid Diagnostic Test for COVID-19 Based on Antibody Detection (YCOVID)
Ycovid-19 aims to be a rapid diagnostic test for SARS-CoV-2 infection, which will allow a reliable diagnosis to be made in 10 minutes, and on easy-to-use devices.
- Trial name
- YCOVID (NCT04490837)
- Testing
- ELISA and Rapid test to detect antibodies against COVID-19
- Where
- Spain
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
COVID-19, SARS-CoV Infection
Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection
This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210 individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who came to the study site with clinical and…
- Conditions
- COVID-19, SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Clinical Trial
- Trial name
- CloroCOVID19II (NCT04342650)
- Testing
- Chloroquine Diphosphate
- Where
- Brazil
- Volunteers
- 152 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
COVID-19
Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19
The objective is to determine the efficacy, immunogenicity and safety of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the efficacy and safety in prophylaxis…
- Trial name
- NCT04824391
- Testing
- ERUCOV-VAC 3 µg/0.5 ml Vaccine, ERUCOV-VAC 6 µg/0.5 ml Vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Health Institutes of Turkey
Myalgic Encephalomyelitis, Long-COVID
Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
The goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy.
- Trial name
- NCT06257420
- Testing
- Rapamycin
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Simmaron Research Inc.
COVID 19
Anti COVID-19 Convalescent Plasma Therapy
Why is the research needed? The pandemic known as COVID-19 is now spreading across the world with currently (April 10, 2020) more than 1 115 530 active cases and 96 791 deaths.
- Trial name
- NCT04345679
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- Hungary
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orthosera Kft.
SARS-CoV-2
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an…
- Trial name
- NCT04796896
- Testing
- mRNA-1273, mRNA-1273.214
- Where
- 91 sites in United States, Canada
- Volunteers
- 11,942 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.